Seelos Therapeutics, Inc.
NASDAQ:SEEL
Overview | Financials
Company Name | Seelos Therapeutics, Inc. |
Symbol | SEEL |
Currency | USD |
Price | 0.37 |
Market Cap | 214,970 |
Dividend Yield | 0% |
52-week-range | 0.37 - 0.37 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Raj Mehra J.D., Ph.D. |
Website | https://seelostherapeutics.com |
An error occurred while fetching data.
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD